Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1988 Jul;94(3):924–932. doi: 10.1111/j.1476-5381.1988.tb11605.x

Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

J A Stamford 1, Z L Kruk 1, J Millar 1
PMCID: PMC1854028  PMID: 2902896

Abstract

1. Fast cyclic voltammetry at carbon fibre microelectrodes was used to study the effects of several dopamine antagonists upon stimulated dopamine release in the rat striatum and nucleus accumbens. 2. In both nuclei, stimulated dopamine release was increased by D2-receptor-selective and mixed D1/D2-receptor antagonists. The D1-selective antagonist SCH 23390 had no effect. 3. Striatal and limbic dopamine release were elevated by cis- but not trans-flupenthixol. 4. The 'atypical' neuroleptics (clozapine and thioridazine) did not cause a selective elevation of dopamine release in the limbic terminal region, whereas the non-antipsychotic drug metoclopramide increased dopamine release more in striatum than nucleus accumbens. 5. We conclude from this study that striatal and limbic dopamine release are under the control of a stereoselective dopamine D2-autoreceptor on the nerve terminal and that atypical neuroleptics do not show a limbic-selective effect at this receptor after acute administration.

Full text

PDF
924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altar C. A., Hauser K. Topography of substantia nigra innervation by D1 receptor-containing striatal neurons. Brain Res. 1987 Apr 28;410(1):1–11. doi: 10.1016/s0006-8993(87)80014-8. [DOI] [PubMed] [Google Scholar]
  2. Andersen P. H., Grønvald F. C., Jansen J. A. A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci. 1985 Nov 25;37(21):1971–1983. doi: 10.1016/0024-3205(85)90028-1. [DOI] [PubMed] [Google Scholar]
  3. Arbilla S., Langer S. Z. Stereoselectivity of presynaptic autoreceptors modulating dopamine release. Eur J Pharmacol. 1981 Dec 17;76(4):345–351. doi: 10.1016/0014-2999(81)90105-9. [DOI] [PubMed] [Google Scholar]
  4. Armstrong-James M., Millar J. Carbon fibre microelectrodes. J Neurosci Methods. 1979 Oct;1(3):279–287. doi: 10.1016/0165-0270(79)90039-6. [DOI] [PubMed] [Google Scholar]
  5. Bartholini G. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol. 1976 May;28(5):429–433. doi: 10.1111/j.2042-7158.1976.tb04648.x. [DOI] [PubMed] [Google Scholar]
  6. Boyar W. C., Altar C. A. Modulation of in vivo dopamine release by D2 but not D1 receptor agonists and antagonists. J Neurochem. 1987 Mar;48(3):824–831. doi: 10.1111/j.1471-4159.1987.tb05591.x. [DOI] [PubMed] [Google Scholar]
  7. Chiodo L. A., Bunney B. S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983 Aug;3(8):1607–1619. doi: 10.1523/JNEUROSCI.03-08-01607.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clement-Cormier Y. C., Kebabian J. W., Petzold G. L., Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci U S A. 1974 Apr;71(4):1113–1117. doi: 10.1073/pnas.71.4.1113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Costall B., Funderburk W. H., Leonard C. A., Naylor R. J. Assessment of the neuroleptic potential of some novel benzamide, butyrophenone, phenothiazine and indole derivatives. J Pharm Pharmacol. 1978 Dec;30(12):771–778. doi: 10.1111/j.2042-7158.1978.tb13390.x. [DOI] [PubMed] [Google Scholar]
  10. Crow T. J., Deakin J. F., Longden A. The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs? Psychol Med. 1977 May;7(2):213–221. doi: 10.1017/s0033291700029287. [DOI] [PubMed] [Google Scholar]
  11. Dawson T. M., Gehlert D. R., McCabe R. T., Barnett A., Wamsley J. K. D-1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J Neurosci. 1986 Aug;6(8):2352–2365. doi: 10.1523/JNEUROSCI.06-08-02352.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dawson T. M., Gehlert D. R., Yamamura H. I., Barnett A., Wamsley J. K. D-1 dopamine receptors in the rat brain: autoradiographic localization using [3H]SCH 23390. Eur J Pharmacol. 1985 Feb 5;108(3):323–325. doi: 10.1016/0014-2999(85)90458-3. [DOI] [PubMed] [Google Scholar]
  13. Dray A. The striatum and substantia nigra: a commentary on their relationships. Neuroscience. 1979;4(10):1407–1439. doi: 10.1016/0306-4522(79)90048-4. [DOI] [PubMed] [Google Scholar]
  14. Elliott P. N., Jenner P., Huizing G., Marsden C. D., Miller R. Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology. 1977 May;16(5):333–342. doi: 10.1016/0028-3908(77)90070-3. [DOI] [PubMed] [Google Scholar]
  15. Ewing A. G., Bigelow J. C., Wightman R. M. Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. Science. 1983 Jul 8;221(4606):169–171. doi: 10.1126/science.6857277. [DOI] [PubMed] [Google Scholar]
  16. Filloux F. M., Wamsley J. K., Dawson T. M. Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390. Brain Res. 1987 Apr 7;408(1-2):205–209. doi: 10.1016/0006-8993(87)90373-8. [DOI] [PubMed] [Google Scholar]
  17. Fleminger S., van de Waterbeemd H., Rupniak N. M., Reavill C., Testa B., Jenner P., Marsden C. D. Potent lipophilic substituted benzamide drugs are not selective D-1 dopamine receptor antagonists in the rat. J Pharm Pharmacol. 1983 Jun;35(6):363–368. doi: 10.1111/j.2042-7158.1983.tb02957.x. [DOI] [PubMed] [Google Scholar]
  18. Ford A. P., Marsden C. A. Influence of anaesthetics on rat striatal dopamine metabolism in vivo. Brain Res. 1986 Jul 30;379(1):162–166. doi: 10.1016/0006-8993(86)90270-2. [DOI] [PubMed] [Google Scholar]
  19. Gehlert D. R., Wamsley J. K. Autoradiographic localization of [3H]sulpiride binding sites in the rat brain. Eur J Pharmacol. 1984 Feb 17;98(2):311–312. doi: 10.1016/0014-2999(84)90609-5. [DOI] [PubMed] [Google Scholar]
  20. Gerlach J., Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology (Berl) 1978 Oct 31;59(2):105–112. doi: 10.1007/BF00427742. [DOI] [PubMed] [Google Scholar]
  21. Hand T. H., Hu X. T., Wang R. Y. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res. 1987 Jul 14;415(2):257–269. doi: 10.1016/0006-8993(87)90207-1. [DOI] [PubMed] [Google Scholar]
  22. Hand T. H., Kasser R. J., Wang R. Y. Effects of acute thioridazine, metoclopramide and SCH 23390 on the basal activity of A9 and A10 dopamine cells. Eur J Pharmacol. 1987 Jun 4;137(2-3):251–255. doi: 10.1016/0014-2999(87)90230-5. [DOI] [PubMed] [Google Scholar]
  23. Heikkila R. E., Cabbat F. S., Manzino L. Stereospecific binding of 3H-dopamine in neostriatal membrane preparations: inhibitory effects of sodium ascorbate. Life Sci. 1983 May 9;32(19):2183–2191. doi: 10.1016/0024-3205(83)90416-2. [DOI] [PubMed] [Google Scholar]
  24. Herdon H., Strupish J., Nahorski S. R. Endogenous dopamine release from rat striatal slices and its regulation by D-2 autoreceptors: effects of uptake inhibitors and synthesis inhibition. Eur J Pharmacol. 1987 Jun 12;138(1):69–76. doi: 10.1016/0014-2999(87)90338-4. [DOI] [PubMed] [Google Scholar]
  25. Hyttel J. SCH 23390 - the first selective dopamine D-1 antagonist. Eur J Pharmacol. 1983 Jul 15;91(1):153–154. doi: 10.1016/0014-2999(83)90381-3. [DOI] [PubMed] [Google Scholar]
  26. Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature. 1979 Jan 11;277(5692):93–96. doi: 10.1038/277093a0. [DOI] [PubMed] [Google Scholar]
  27. Kuhr W. G., Bigelow J. C., Wightman R. M. In vivo comparison of the regulation of releasable dopamine in the caudate nucleus and the nucleus accumbens of the rat brain. J Neurosci. 1986 Apr;6(4):974–982. doi: 10.1523/JNEUROSCI.06-04-00974.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. LEHMANN H. E., HANRAHAN G. E. Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states. AMA Arch Neurol Psychiatry. 1954 Feb;71(2):227–237. [PubMed] [Google Scholar]
  29. Lehmann J., Arbilla S., Langer S. Z. Dopamine receptor mediated inhibition by pergolide of electrically-evoked 3H-dopamine release from striatal slices of cat and rat: slight effect of ascorbate. Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):31–35. doi: 10.1007/BF00506253. [DOI] [PubMed] [Google Scholar]
  30. Maidment N. T., Marsden C. A. Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in the nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology. 1987 Feb-Mar;26(2-3):187–193. doi: 10.1016/0028-3908(87)90208-5. [DOI] [PubMed] [Google Scholar]
  31. Meller E., Kuga S., Friedhoff A. J., Goldstein M. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life Sci. 1985 May 13;36(19):1857–1864. doi: 10.1016/0024-3205(85)90159-6. [DOI] [PubMed] [Google Scholar]
  32. Millar J., Stamford J. A., Kruk Z. L., Wightman R. M. Electrochemical, pharmacological and electrophysiological evidence of rapid dopamine release and removal in the rat caudate nucleus following electrical stimulation of the median forebrain bundle. Eur J Pharmacol. 1985 Mar 12;109(3):341–348. doi: 10.1016/0014-2999(85)90394-2. [DOI] [PubMed] [Google Scholar]
  33. Nauta W. J., Domesick V. B. Afferent and efferent relationships of the basal ganglia. Ciba Found Symp. 1984;107:3–29. doi: 10.1002/9780470720882.ch2. [DOI] [PubMed] [Google Scholar]
  34. Onali P., Mereu G., Olianas M. C., Bunse B., Rossetti Z., Gessa G. L. SCH 23390, a selective D1 dopamine receptor blocker, enhances the firing rate of nigral dopaminergic neurons but fails to activate striatal tyrosine hydroxylase. Brain Res. 1985 Aug 5;340(1):1–7. doi: 10.1016/0006-8993(85)90769-3. [DOI] [PubMed] [Google Scholar]
  35. Reid M. Dystonic reactions to metoclopramide (maxolon). Ulster Med J. 1977;46(1):38–40. [PMC free article] [PubMed] [Google Scholar]
  36. Scatton B., Dubois A. Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SKF 38393. Eur J Pharmacol. 1985 Apr 23;111(1):145–146. doi: 10.1016/0014-2999(85)90128-1. [DOI] [PubMed] [Google Scholar]
  37. Seeman P. Brain dopamine receptors. Pharmacol Rev. 1980 Sep;32(3):229–313. [PubMed] [Google Scholar]
  38. Simpson G. M., Lee J. H., Shrivastava R. K. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978 Jan 31;56(1):75–80. doi: 10.1007/BF00571412. [DOI] [PubMed] [Google Scholar]
  39. Stamford J. A., Kruk Z. L., Millar J. Sub-second striatal dopamine release measured by in vivo voltammetry. Brain Res. 1986 Sep 3;381(2):351–355. doi: 10.1016/0006-8993(86)90087-9. [DOI] [PubMed] [Google Scholar]
  40. Stanley M., Lautin A., Rotrosen J., Gershon S., Kleinberg D. Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology (Berl) 1980;71(3):219–225. doi: 10.1007/BF00433055. [DOI] [PubMed] [Google Scholar]
  41. Stawarz R. J., Hill H., Robinson S. E., Setler P., Dingell J. V., Sulser F. On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. Psychopharmacologia. 1975 Aug 21;43(2):125–130. doi: 10.1007/BF00421014. [DOI] [PubMed] [Google Scholar]
  42. Stoof J. C., Kebabian J. W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 1984 Dec 3;35(23):2281–2296. doi: 10.1016/0024-3205(84)90519-8. [DOI] [PubMed] [Google Scholar]
  43. White F. J., Wang R. Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983 Sep 9;221(4615):1054–1057. doi: 10.1126/science.6136093. [DOI] [PubMed] [Google Scholar]
  44. Zetterström T., Sharp T., Ungerstedt U. Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1986 Oct;334(2):117–124. doi: 10.1007/BF00505810. [DOI] [PubMed] [Google Scholar]
  45. de Belleroche J. S., Neal M. J. The contrasting effects of neuroleptics on transmitter release from the nucleus accumbens and corpus striatum. Neuropharmacology. 1982 Jun;21(6):529–537. doi: 10.1016/0028-3908(82)90043-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES